



Interorganellar Communication in Health and Disease

Mini-symposium

4.12.2023, 14:00 - 16:00

DIONÝZ BLAŠKOVIČ'S LECTURE HALL,
BIOMEDICAL RESEARCH CENTER

14:00-14:30 MARKETA BEBAROVA

14:30-15:00 JAN SKODA

15:00-15:30 LIGA ZVEJNIECE

15:30-16:00 REINIS VILSKERSTS

Drug-channel interactions studied in isolated cardiomyocytes

Assoc. Prof. Markéta Bébarová, M.D., Ph.D., the head of the Research Group on Excitability and its Disorders, Department of Physiology, Faculty of Medicine, Masaryk University, is an internationally recognized expert on cardiac cell electrophysiology. The group mostly focuses on the analysis of drug-channel interactions as well as of genetically-based cardiac ionic channel dysfunctions associated with inherited arrhythmias. The lecture will be focused on the technique of enzymatic isolation of cardiomyocytes and their use for the analysis of the effects of selected drugs on inward rectifier potassium current I_{K1} and action potential configuration.



Mitoribosomal synthetic lethality for cancer therapy

Dr. Jan Škoda, Ph.D., the leader of the Laboratory Oncology Translational Research group, International Clinical Research Center, St. Anne's University Hospital, Brno, is a cancer biologist with a major focus on identifying molecular targets for the treatment of aggressive therapy-resistant childhood tumors. His work has contributed to the discovery of a novel mechanism of cancer multidrug resistance that involves changes in the mitochondria-endoplasmic reticulum contact sites. The talk will focus on aspects of this mitochondrial resistance and will introduce new insights into how mitochondria can be therapeutically exploited to target multidrug-resistant tumor cells.



For further information contact: michal.cagalinec@savba.sk; saschia.zahradnikova@savba.sk



The project "Alliance for Life Sciences: From Strategies to Actions in Central and Eastern Europe" received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 964997.



Interorganellar Communication in Health and Disease

Mini-symposium

4.12.2023, 14:00 - 16:00

DIONÝZ BLAŠKOVIČ'S LECTURE HALL,
BIOMEDICAL RESEARCH CENTER

14:00-14:30 MARKETA BEBAROVA

14:30-15:00 JAN SKODA

15:00-15:30 LIGA ZVEJNIECE

15:30-16:00 REINIS VILSKERSTS

Sigma-1 receptor: the intracellular target of neurodegenerative drugs

Dr.M., Liga Zvejniece, PhD has more than 20 years of experience in interdisciplinary pharmacological research involving animal behavior, CNS and metabolic diseases, expertise in the proof of concept for novel drug target discovery, and screening of biological activity and preclinical evaluation of drug candidates. L.Zvejniece works in Sigma-1 receptor field for more than 10 years. She has published 7 international publications and 3 patents related to Sigma-1 receptor modulation. She has experience in management of academic research grants, Technology Transfer projects, the European Regional Development Fund (ERDF) projects, as well as international collaboration projects.



Long-chain acylcarnitine content lowering therapy for the treatment of cardiovascular diseases

Assoc. Prof. Dr. pharm. Reinis Vilskersts is a leading researcher in Laboratory of Pharmaceutical Pharmacology at Latvian Institute of Organic Synthesis. He has been involved in studies assessing the effects of modification of energy metabolism on the development of cardiovascular diseases. The lecture will be focused on the deleterious effects of fatty acid metabolism intermediates long-chain acylcarnitines.



For further information contact: michal.cagalinec@savba.sk; saschia.zahradnikova@savba.sk



The project "Alliance for Life Sciences: From Strategies to Actions in Central and Eastern Europe" received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 964997.